Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
efineptakin alfa
- Development stage
- Phase 2
- Lead developer
- NeoImmuneTech
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Administration
- Intramuscular, Mucosal, Vaginal
01
Overview
Efineptakin alfa is a long-acting recombinant human interleukin-7 (IL-7) fusion protein engineered by fusing IL-7 to a hybrid Fc (hyFc) region of a human antibody. This design increases its stability and half-life compared to endogenous IL-7. Efineptakin alfa acts as an immunotherapy by promoting T-cell development and proliferation, thereby enhancing immune responses against cancer and other diseases characterized by T-cell deficiency. It is being developed for use in oncology (including solid tumors such as pancreatic cancer, glioblastoma multiforme, triple-negative breast cancer), immunology (such as idiopathic CD4 lymphocytopenia), and infectious diseases (including COVID-19). The drug is administered via intramuscular injection or mucosal delivery routes.
- Brand names
- HyLeukin
- Other names
- NT-I7NT-I-7NT-I 7GX-I7GX-I-7GX-I 7rhIL-7-hyFcrhIL7-hyFcrhIL 7-hyFc
02
Targets
IL7R (Interleukin-7 Receptor)
Beyond the preview
Go deeper on efineptakin alfa.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on efineptakin alfa.